Cover Image

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Zhidong Zhou, Nanren Sun, Qiang Liu
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
by: Antoine Meyer, et al.
Published: (2025)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
by: Rónán O'Connor, et al.
Published: (2026)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
by: Richard Pollok
Published: (2025)

Letter: Exclusive Enteral Nutrition in Ulcerative Colitis—The Path Ahead Needs Careful Consideration
by: Sarah Melton, et al.
Published: (2025)

Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply
by: Ankit Kumar, et al.
Published: (2026)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease
by: Jiacheng Li
Published: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
by: Tamar Schildkraut, et al.
Published: (2024)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
by: Merle Claßen, et al.
Published: (2024)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis
by: Ganesh Bhat, et al.
Published: (2026)

Editorial: Striving for Equitable Care in Ulcerative Colitis
by: Edward L. Barnes
Published: (2025)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
by: Kuan‐Ju Lin, et al.
Published: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
by: José Luis Rueda García, et al.
Published: (2026)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
by: Amol N. Patil, et al.
Published: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
by: Virginia Solitano, et al.
Published: (2024)

Meta‐Analysis: Exclusive Enteral Nutrition in Adults With Ulcerative Colitis
by: Matthew K. W. Chu, et al.
Published: (2025)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
by: Ziheng Calvin Xu, et al.
Published: (2025)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
by: Anish J. Kuriakose Kuzhiyanjal, et al.
Published: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
by: Dingsheng Liu, et al.
Published: (2025)

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
by: Emmanuel Pio Pastore
Published: (2025)

Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT ‐ UC Consortium
by: Brian C. Weiner
Published: (2025)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
by: Ahmed B. Bayoumy, et al.
Published: (2025)

Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis
by: Arshdeep Singh, et al.
Published: (2025)

Editorial: Evolving Trends in Ulcerative Colitis Management—Insights From the Lothian Cohort
by: Shintaro Akiyama
Published: (2025)

Temporal Trends in Medical and Surgical Management of Ulcerative Colitis in England: 2003–2020
by: J. Couch, et al.
Published: (2025)

Editorial: The Appendix—A Dead End for Treating Ulcerative Colitis, After All?
by: Johan D. Söderholm
Published: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
by: Joyce Wing Yan Mak
Published: (2025)

Letter: Critical Insights on a Nationwide Cohort Study of Inflammatory Bowel Disease, Histological Activity and Fracture Risk
by: Saad Khan, et al.
Published: (2024)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse
by: Mark A. Ainsworth, et al.
Published: (2025)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter: Authors' Reply
by: Aakash Desai, et al.
Published: (2025)

Letter : Is Short Tapering of Steroids in Moderate to Severely Active Ulcerative Colitis Really Inferior to a Long Steroid Taper, or Just Underpowered to Reach a Definitive Conclusion?
by: Hariti Saluja, et al.
Published: (2026)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
by: Chang Liu, et al.
Published: (2026)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
by: Alice S. Day, et al.
Published: (2025)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
by: Matthias Kelm, et al.
Published: (2025)

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity
by: Brigida Barberio, et al.
Published: (2026)

Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study
by: Tom van Gils, et al.
Published: (2024)

The Association of Faecal Calprotectin Measurements With Endo‐Histological Remission in Ulcerative Colitis: A Pooled Analysis
by: Laurie‐Rose Dubé, et al.
Published: (2026)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
by: Aurelien Amiot, et al.
Published: (2025)

Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
by: Maryam Irshad, et al.
Published: (2025)

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study
by: Mathilde Osty, et al.
Published: (2025)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse. Authors' Reply
by: Shinichiro Shinzaki, et al.
Published: (2025)